Regulus Therapeutics Inc. announced Jake Nunn and Simos Simeonidis, Ph.D. have been appointed to the Company's board of directors. Concurrently with their appointments to the Board, Mr. Nunn was appointed to serve on the Audit Committee and Dr. Simeonidis was appointed to serve on the Corporate Governance & Nominating Committee. Mr. Nunn is currently a venture advisor at New Enterprise Associates Inc. Prior to joining NEA, he served as a partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P. Dr. Simeonidis is a Partner at Sarissa Capital. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. In addition to his investment management and financial expertise, Dr. Simeonidis combines both biopharmaceutical industry and biomedical research expertise, having worked at Novartis in Business Development and Strategic Planning, and prior to his corporate career, having served as a faculty member at Harvard Medical School.